The United States Food and Drug Administration (USFDA) carried out the inspection of the company's Vizag API manufacturing facility between January 13, 2020 and January 17, 2020.
USFDA issued a warning letter to Lupin for violation of current good manufacturing practice norms at two of its manufacturing facilities in Goa and Indore
